natgillin/translations-raw huggingface dataset:
A pharmaceutical aerosol solution composition according to claim 3 wherein a mineral acid is an amount of acid equivalent to 0.22 µg/µl of 1M hydrochloric acid. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 3 u kojem mineralna kiselina jest količina kiseline ekvivalentna 0.22 ug/ul od 1M klorovodične kiseline.
A pharmaceutical composition deliverable from a metered dose inhaler, comprising; 
Farmaceutski pripravak koji se može isporučiti iz inhalatora s odmjerenom dozom, koji sadrži:
The system of claim 1 wherein the at least one processor dynamically determines the estimated transit time for the respective vehicle to at least one of the plurality of destinations to be visited during the route based at least in part on an update of the respective route the vehicle is to transit. 
radio uređaj koji je komunikacijski spojen s najmanje jednom upravljačkom jedinicom (222) za proizvodnju signala koji pokazuju najmanje jednu dinamički ažuriranu temperaturu i/ili jedno dinamički ažurirano vrijeme kuhanja za barem jedan od štednjaka (210), gdje se signali zaprimaju iz udaljenog stacioniranog izvora (102).
A system according to any one of claims 2-7, wherein each ridge of the plurality of ridges has substantially the same width. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je ispupčeni dio (127) napravljen od istog materijala kao čašica.
(CO2R") and (COR"') are attached to the same atom of the Z ring; as well as their enantiomers, diastereoisomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters. 
HR P20080431 T3 (CO2R") i (COR'") su vezani na isti atom u Z prstenu; kao i njegovi enantiomeri, dijastereoizomeri, njihove smjese, slobodni oblici i farmaceutski prihvatljive soli, hidrati, te solvati.
The rock bolting system as claimed in claim 1, characterized in that the suspension element (16) comprises one of the following: a mounting lug, a single hook, a double hook, a crook or a combination thereof. 
Sistem sidrenja u stijeni prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da ovjesni element (16) sadrži jedno od slijedećeg: montažnu ušku, jednostruku kuku, dvostruku kuku, kvaku ili njihovu kombinaciju.
The amount of the compound present in compositions is such that a suitable dosage will be obtained. 
Količina spoja prisutna u pripravcima je takva da se postigne pogodna doza.
18, 19, 20 or 62 and a light chain comprising the amino acid sequence SEQ ID No. 
1,21 3, laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 te sadrži aminokiselinsku sekvenciju SEQ ID No.
An oligosaccharide-lysosomal enzyme conjugate, comprising (1) a lysosomal enzyme, (2) an oligosaccharide, and (3) an oxime group connecting the lysosomal enzyme and the oligosaccharide, wherein the oligosaccharide is an oligosaccharide of Formula VI: 
Konjugat oligosaharid-protein, koji sadrži (1) protein, (2) oligosaharid, te (3) oksimsku skupinu koja spaja protein i oligosaharid naznačen time da oligosaharid je oligosaharid s Formulom VI: [image]
with a methylating agent in a suitable solvent to afford Compound B of the formula 
Spoj A sa sredstvom za metiliranje u odgovarajućem otapalu radi dobivanja Spoja B formule
The fermentation broth is cycled past a filter and becomes increasingly concentrated with each cycle because of water loss through the filter. 
Fermentacijski bujon ciklički prolazi kroz filter te mu sa svakim ciklusom raste koncentracija zbog gubitka vode kroz filter.
A demountable pole dancing stage as claimed in any preceding claim, wherein at least one of the support members is provided with a radially extendable secondary support member, which can extend radially beyond the support member to bear on the ground. 
Sklopiva pozornica za ples na šipki iz bilo kojeg prethodnog zahtjeva, pri čemu bar jedan od nosivih elemenata ima vodoravno produljivi sekundarni nosivi element koji se može izvući iz primarnog nosivog elementa i položiti na tlo (podlogu).
The method according to clause 6, wherein said daily dose is about 10 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 4, pri čemu je navedena dnevna doza oko 10 mg/dan.
The compound of claim 2 wherein R1 is a substituted C1-6 alkyl of the formula where R8, R9 are both methyl or linked to form a cyclopropyl, cyclobutyl, cyclopentyl or a cyclohexyl group; 
je supstituirani C1-6-alkil formule [image] pri čemu svaki od R8 i R9 je metil, ili su povezani za tvorbu ciklopropil-, ciklobutil-, ciklopentil- ili cikloheksil-skupine;
Three 14 mL milk samples were prepared in duplicate in 20 ML SPME (solid phase micro-extraction) vials (flat bottom (23 mm×75 mm) headspace vial with PTFE lined silicone closure (cat. no. 27199 and 27300) ex Supelco®) in a glove box under a carbon dioxide atmosphere and sealed tight. Samples A and C: Milk without addition 
Tri uzorka mlijeka od 14 mL se pripreme u duplikatu u 20mL SPME (solid phase micro-extraction - mikroekstrakcija na čvrstoj fazi) bočicama (ravno dno (23mm x 75mm) gornji prostor bočice s PTFE obloženim silikonskim zatvaračem (kat. br. 27199 i 27300) iz Supelco*) u pristajućoj kutiji pod atmosferom ugljik dioksida i hermetički zatvore.
a peptide for conjugating europium clathrates for fluorescence resonance energy transfer (FRET)-based proximity assays, and 
(k) peptida za konjugiranje klatrata europija za blizinske testove bazirane na fluorescentnom rezonantnom prijenosu energije (FRET) 1
Procedure according to one or more of the preceding claims, wherein said packaging sheet (2) is heat-sealable and said sealing longitudinally and said sealing transversally are hot. 
Postupak prema jednom ili više od prethodnih patentnih zahtjeva, naznačen time što navedeni materijal (2) za pakiranje u listovima se može zatvarati toplinom i navedeno uzdužno zatvaranje i navedeno poprečno zatvaranje se događaju na vrućini.
at least one condensed polycyclic system, which is aliphatic or partly aromatic or also wholly aromatic, each ring comprising 5 or 6 atoms, alone or in a mixture. 
najmanje jednog kondenziranog policikličkog sustava, koji je alifatski, ili djelomično aromatski ili također posve aromatski, gdje svaki prsten sadrži 5 ili 6 atoma, samog ili u smjesi.
Cortexolone-17a-propionate in crystalline form I according to claim 12 or 13 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u hidratnom kristalnom obliku IV u skladu s bilo kojim od patentnih zahtjeva 21 do 22, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožnih adneksa.
mixing the antigen-presenting cell of step (i) with a CD8+ T cell and co-culturing, wherein the peptide is selected from the group consisting of: 
(ii) miješanja stanice za predočavanje antigena iz koraka (i) s CD8+ T-stanicom i suuzgoj.
The solid salt form of claim 6, wherein the a-6-mPEG6-O-hydroxycodone D-tartrate salt is a monotartrate salt. 
Čvrsti oblik soli iz patentnog zahtjeva 6, naznačen time, što je a-6-mPEG6-O-hidroksikodon D-tartaratna sol monotartaratna sol.
The term “halogen” or “halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with bromine, chlorine or fluorine being preferred. 
Termin "halogen" ili "halo" kao što se ovdje upotrebljava samostalno ili kao dio druge skupine odnosi se na klor, brom, fluor i jod, poželjno sa bromom, klorom ili fluorom.
The process of claim 1 or claim 2, further comprising operating the first reaction stage (14) at a temperature and pressure to hydrocrack the resid at an overall resid conversion of at least 60 wt.%. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća djelovanje prvog reakcijskog stupnja (14) na temperaturi i tlaku za hidrokrekiranje ostatka uz ukupnu konverziju ostatka od najmanje 60 % težinskog udjela.
After filling lyophilization stoppers were placed and the vials loaded in the lyophiliser at 5°C. Lyophilization process was performed as before for Formulations ET-NF A, ET-NF B and ET-NF F (Table IX). 
Nakon toga su postavljeni čepovi za liofilizaciju i ampule su postavljene u liofilizator na 5*C. Proces liofilizacije je izveden kao u prethodnom slučaju za oblike ET-NF A, ET-NF B i ET-NF F (Tablica IX).
An isolated host cell comprising the vector of claim 6 . The host cell of claim 7, which is a human cell. 
Stanica domaćin u skladu s patentnim zahtjevom 7, naznačena time, da je to ljudska stanica.
wherein the light chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues at positions 38, 39, and 43 in HA2 of said proximal monomer, and amino acid residues at positions 327, 328, and 329 in HA1 and 1, 2, 3, and 4 in HA2 of said distal right monomer, and wherein said proximal and said distal right monomers are uncleaved, or 
protutijelo, ili njegov ulomak koji veže antigen u kojem laki lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima na položajima 38, 39, i 43 u HA2 navedenog proksimalnog monomera, i aminokiselinskim ostatcima na položajima 327, 328, i 329 u HA1 i 1, 2, 3, i 4 u HA2 navedenog distalnog desnog monomera, i pri čemu navedeni proksimalni i navedeni distalni desni monomeri se ne cijepaju;
The compound or the pharmaceutical composition for use of claim 7, wherein the disease is cancer. 
Spoj za uporabu u postupku prema patentnom zahtjevu 11, naznačen time, da je bolest karcinom.
Table 10: Compositions of the formulations 
Broj objave europskog patenta:
The wet material was refluxed in 300 ml of methanol for 30 min and then filtered through a hyflow bed. 
Vlažni materijal je doveden do refluksa u 300 ml metanola tijekom 30 minuta a zatim profiltriran kroz hyflow podlogu.
If the size of the current block is equal to or smaller than a predetermined size, the filter may not be applied. 
Uređaj prema zahtjevu 1, naznačen time, da je veličina koraka kvantizacije određena po bloku kodirajuće unaprijed određene veličine.
adding sulphuric acid to said first leach solution after said step of removing said precipitated phosphate compounds, causing precipitation of sulphate compounds; 
dodavanje (240) sumporne kiseline u spomenutu prvu otopinu za ispiranje nakon spomenutog koraka uklanjanja (225) spomenutih istaloženih fosfatnih spojeva, čime se izaziva taloženje sulfatnih spojeva;
After the end of the oxidation, undesired compounds are removed in the following way. 
Nakon oksidacije neželjene spojevi se uklanja na sljedeći način.
A portable service bar according to claim 1, characterized in that in an operable position ready to use, and wherein the at least one front wall comprises two front walls, the two front walls are included in the portable service bar and the two top front plates are arranged in a position wherein the edges of the two top front plates facing each other are abutting. 
Prijenosno uslužno mjesto prema jednom od prethodnih zahtjeva, naznačeno time da su u radnom položaju kada je spremno za korištenje, dvije prednje stranice (2) koje su sadržane u prijenosnom uslužnom mjestu i dvije najgornje prednje ploče (5) postavljene u položaj gdje se dodiruju rubovi dviju najgornjih prednjih ploča (5) koji su okrenuti jedan prema drugom.
Preferably, the compounds of general formula (I) as defined above are prepared by condensation, in the presence of a suitable condensing agent, of the intermediate of general formula (II), obtained as disclosed in WO03103671 with the compound of formula (10) 
Profcrirano sc spojevi opće formule (I), kao što je gore definirano, pripravljaju kondenzacijom međuprodukta opće formule (II), u prisutnosti pogodnog sredstva za kondenzaciju, a koji je dobiven kako je prikazano u WO03103671. t h /
The system according to claim 1, wherein the software module includes an image enhancement module to enhance bony surface details in the selected ultrasound images. 
Sustav (10) prema zahtjevu 1, naznačen time da softverski modul (21) uključuje modul poboljšanja slika za poboljšanje detalja koštane površine na snimljenim slikama.
The reaction mixture was then allowed to warn to room temperature and it was stirred overnight. 
Reakcijska se smjesa potom ugrije na sobnu temperaturu i miješa preko noći.
• a component of charging the system if the state of charge of the power storage system is below the target SOC, and 
* komponenta punjenja sustava ako je stanje napunjenosti sustava za pohranu energije ispod ciljanog SOC, i
In these Examples the base elastomer, in a grade suitable for use in a pharmaceutical vial closure, was supplied from the suppliers indicated below. 
U ovim primjerima je osnovni elastomer, u stupnju čistoće koji je prikladan za upotrebu u zatvaračima farmaceutskih bočica, bio dobavljen od dobavljača koji su navedeni ovdje dolje.
An agomelatine hydrochloride hydrate of formula I according to claim 1 in the form of crystalline form, characterized by Bragg 2θ angle, interplanar spacing d and relative intensity as follows: 2-Theta 
Agomelatin hidroklorid hidrat formule I u skladu s patentnim zahtjevom 1, u kristalnom obliku, naznačen time, da su Braggov kut 20, interplanarni razmak D i relativni intenzitet kako slijedi: 2-Theta
-[4-(1-Amino-propyl)-4-phenyl-cyclohexyloxy]-4-bromo-7-chloro-2H-isoquinolin-1-one, their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts thereof. 
-[4-(1-amino-propil)-4-fenil-cikloheksiloksi]-4-bromo-7-kloro-2H-izokinolin-1-on, njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
A pharmaceutical composition according to claim 8, for treatment of a condition selected from the group consisting of mood and anxiety disorders, depression and obsessive-compulsive disease. 
Farmaceutski pripravak prema zahtjevu $, naznačen time, što je za liječenje stanja odabranih iz skupine koja so sastoji od poremećaja raspoloženja i anksioznosti, depresije i opsesivno-kompulzivnog poremećaja.
the variable light chain sequence of SEQ ID NO: 86 and variable heavy chain sequence of SEQ ID NO: 100; 
(b) varijabilno područje slabog lanca od sekvence SEQ ID NO: 86, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 100;
is —NHS(═O)2R8, wherein R8 is cyclopropyl substituted with methyl. The combination according to claim 10, wherein 
(0) R' je -NHS(S0)R*, pri čemu Rž je ciklopropil koji je supstituiran sa metilom.
The method according to claim 1, wherein the hollow bodies (11) are constructed as earth-improvement hollow bodies (11), having their hollow interior spaces filled with a carbon-contained substance (113) or an earth-improvement agent. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su šuplja tijela (11) konstruirana kao šuplja tijela za poboljšavanje tla (11), čiji su šuplji unutarnji prostori ispunjeni tvari koja sadrži ugljik (113) ili sredstvom za poboljšavanje tla.
Such methods include, but are not limited to, centrifuge, filtration funnel, belt filtration, or press filtration. 
Takvi postupci uključuju, ali nisu time ograničeni, centrifugiranje, filtraciju kroz lijevak, pojasnu filtraciju ili filtraciju pod tlakom.
The casts have been analyzed by computerized optical prophylometry according to a validated method. 
Odljevci su analizirani kompjuteriziranom optičkom profilometrijom prema važećoj metodi.
The method of claim 7 or 8, wherein the block includes constellation values in the four sub-blocks when a value of the L1 TI mode information corresponds to '10' and wherein the block includes constellation values in the eight sub-blocks when the value of the L1 TI mode information corresponds to `11'. 
Metoda iz patentnog zahtjeva 7 ili 8, pri čemu blok uključuje konstelacijske vrijednosti u četiri podbloka kada vrijednost informacije vrste L1 TI odgovara '10' i pri čemu blok uključuje konstelacijske vrijednosti u osam podblokova kada vrijednost informacije vrste L1 TI odgovara '11'.
the single nucleotide polymorphism marker having a G at the position corresponding to position 87 in SEQ ID NO:3, 
marker polimorfizma jednostrukog nukleotida koji ima G na položaju koji odgovara položaju 87 u SEQ ID NO:3,
A Cytotoxic conjugate comprising a cell binding agent and a cytotoxic agent, wherein said cell-binding agent comprises the humanized antibody or epitope-binding fragment thereof of claims 1-3. 
Citotoksični konjugat, naznačen time što obuhvaća tvar koja se veže za stanicu i citotoksičnu tvar, pri čemu ta tvar koja se veže za stanicu obuhvaća humanizirano protutijelo ili njegov fragment koji se veže za epitop prema zahtjevima 1-3.
The method according to claim 1, wherein said membrane is heated to approximately 100-150°C. for 10 seconds so as to be firmly coupled to the upper by pressing at approximately 6 bars. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da navedena membrana (13) zagrijava se na oko 100 - 150 "C tijekom 10 sekundi kako bi se prešanjem s tlakom od oko 6 bara ostvario čvrsti spoj s gornjištem (12).
Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for treating, preventing or ameliorating a disorder in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor, and wherein the disorder is preferably selected from the group consisting of pain, diarrhea, or emesis. 
Uporaba spoja prema Formuli I naznačena time da je za proizvodnju lijeka za liječenje, sprečavanje ili ublažavanje poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora, te gdje je poremećaj bol, pri čemu spoj sa formulom I je: [image] gdje A je aril ili heteroaril;
4, the effects of the aspiration of the pump 40 will manifest themselves, in cascade fashion, in the first chamber 27 of the guide 6, on the third suction cup 5 and in the second chamber 37 of the guide 6 . 
Naročito će se pozivom na sliku 4 pokazati djelovanje usisavanja same pumpe 40, u kaskadnom djelovanju, na treću usisnu čašicu 5 i na drugu komoru 37 vodilice 6.
Stirring was kept for 16 hours. 
Miješanje je nastavljeno 16 sati.
Process of manufacturing a compound according to anyone of claims 1 to 5, characterized in that it comprises: 
Postupak proizvodnje spoja sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da sadrži: a) = reakciju spoja formule (i):
The pipette was connected to the headstage of the patch clamp amplifier (Axopatch 200B, Axon Instruments) via a silver/silver chloride wire. 
Pipeta je potom spojena sa glavnim djelom pojačala za patch-pipetu (Axopatch 200B, Axon Instruments) preko žice od srebro/srebroklorida.
After 30 minutes, benzyl bromide (75 µL, 0.63 mmol) is added and the reaction stirred for 3 days, before partitioning between water and 1:1 EtOAc/ether. 
Nakon 30 minuta doda se benzil bromid (75 ul, 0,63 mmola) i reakcijsku smjesu se miješa 3 dana prije nego se podijeli između vode i 1:1 EtOAc/etera.
X1-X4 is independently selected from the group consisting of C and N; 
Xi do X, su neovisno odabrani iz skupine koju čine Ci N;
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil- in-water liquid emulsion or a water-in-oil liquid emulsion. 
Pripravci sukladno predmetnom izumu koji su prikladni za peroralnu primjenu mogu se pripraviti kao odvojene jedinice poput kapsula, vrećica ili tableta pri čemu svaka sadrži unaprijed utvrđenu količinu djelatnog sastojka; u obliku praška ili granula; u obliku otopine ili suspenzije u vodenoj ili nevodenoj tekućini; ili u obliku tekuće emulzije ulje-u-vodi ili voda-u-ulju.
Sugar replacer granules with particle sizes ranging from 500 µm to 2000 µm can easily be obtained using this process. 
Tim se postupkom može lako dobiti zamjena za šećer veličine granula u rasponu od 500 um do 2000 um.
A napkin according to claim 1, wherein said first and said second adhesive portions together form a strip of adhesive extending along said first surface parallel to said first fold. 
Ubrus u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom
The antibody, conjugate or pharmaceutical composition for use according to claim 8, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemcitabin and cyclophosphamide. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 8, naznačeno time, što kemoterapeutsko sredstvo je odabrano iz skupine koja se sastoji od doksorubicina, cisplatina, taksotere, 5fluoruracila, metotreksata, gemcitabine i ciklofosfamida.
Composition according to claim 1 having a water content of 4 to 7 % by weight (determined by Karl Fischer). 
Pripravak prema patentnom zahtjevu 1, takav da je sadržaj vode od 4 do 7 % masenog udjela (određeno Karl Fischerovom metodom).
A compound according to claim 18, wherein R15 is cyclohexyl, cyclohexylmethyl, tert-butyl, iso-propyl, or iso-butyl. 
Spoj u skladu sa zahtjevom 20, naznačen time, da R15 je cikloheksil, cikloheksilmetil, terc-butil, izo-propil ili izo-butil.
In the method of the invention, it is preferential to use 100 to 5,000 ppm, more preferentially 500 to 3,000 ppm of glycerol or polyglycerol, relative to the dry weight of the said mineral matter. 
Postupak prema jednom od zahtjeva 1 do 20, naznačen time da se koristi 100 do 5,000 ppm, te poželjno 500 do 3,000 ppm, glicerola ili poliglicerola, u odnosu na težinu suhe tvari navedenog mineralnog materijala.
According to a further embodiment of the invention, the bolt is provided with an outside thread in the region of its end that faces the punch plate. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što svornjak (BO) ima vanjski navoj (AG) u području svog kraja najbližeg ploči za žigosanje (ST).
when L3 and L4 each represents hydrogen, reacting a compound of formula (IX), or a suitable salt thereof, 
(d) kada L* i L* svaki predstavljaju vodik, od reakcije spoja sa formulom (IX), ili njegove pogodne soli,
The mood disorder according to claim 1, wherein the mood disorder is a drug-induced symptom of depression. 
Uporaba prema zahtjevu 3, naznačena time, da se kod poremećaja raspoloženja radi o osnovnoj jakoj depresiji.
TABLE 9 Oligonucleotide primers used to generate 
Diikonuklaotidne početnice (primeri) korištene za generiranje himeričkog 158
The prodrug may be a compound of general formula (II): 
Spoj opće formule (II) R1 a R8
After cooling down the solution to room temperature, it was loaded on a SiO2 column, flushed with DCM to push out the phenyl ether, and eluted with EtOAc/Hex (I/3) to afford 1.05 g (72%) of Compound 9.4C as a mixture of olefinic isomers. 
Nakon što se otopina ohladi na sobnu temperaturu, stavljena je na SiO, kolonu, propušten je DCM da istisne fenil eter, te je provedena eluacija sa EtOAc/Hex (1/3) da bi se dobilo 1.05 g (72%) Spoja 9.4C kao smjese olefinskih izomera.
Separating at least a portion of the soaked liquid from the second soaked biomass to create a soaked liquid stream and a second solid stream; wherein the second solid stream comprises the second soaked biomass. 
odvajanja u najmanju ruku dijela namočene tekućine od druge namočene biomase kako bi se dobilo struju namočene tekućine koja se sastoji od suspendirane krutine, monomernog šećera, oligomernih šećera, octene kiseline i furfurala i druge struje krutina; gdje druga struja krutina sadrži drugu namočenu biomasu,
The process according to any one of claims 6-9, wherein the process provides a composition comprising the polysaccharide and a level of protein contamination that is less than 5% by weight protein relative to the total weight of the polysaccharide. 
polisaharid, uz razinu proteinskog onečišćenja koja je manja od 5%, težinski, proteina u odnosu na ukupnu težinu polisaharida.